I’d like to introduce a new blog, monitoring stem cell companies financial and market capitalization monthly – Stem Cell Digest.
their calculation based on analysis of reports of public companies:
Criteria for inclusion are: Between 5 million and 500 million in market value; publicly traded on a North American stock exchange; and the company has, as its primary source of revenue, stem cell related activities. StemCellDigest.Net takes no position on the quality of products, the research, or the financial viability of any company in the sector. They are described here because they meet the criteria set forth and not for any other reason. If your company fits these criteria and is not included, please let us know and it will be added.
(published with permission; creadit: Gary Eastin / Stem Cell Digest)
subscribe by RSS and keep yourself updated!
read and watch more about business this week:
video-interview with Randy Mills – CEO of Osiris Therapeutics – “The Tremendous Therapeutical and Commercial Applications of Mesenchymal Stem Cells” (by BioBusiness.TV)
Q&A with Randall Mills, Osiris Therapeutics (by Pharmaceutical Executive)
Interview with a president of CIRM Alan Trounson – “The Future of Regenerative Medicine” (by (Pharma TV)